SP-16 is under clinical development by Serpin Pharma and currently in Phase II for Myocardial Infarction. According to GlobalData, Phase II drugs for Myocardial Infarction have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SP-16’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SP-16 is under development for the treatment of type 1 diabetes, chemotherapy-induced peripheral neuropathy (CIPN), pneumonia due to SARS-CoV-2 infection and its associated ARDS, type 2 diabetes, myocardial infarction, eosinophilic esophagitis (EoE), chronic inflammatory, demyelinating neuropathy (CIDN), pemphigus vulgaris, acute kidney injury, atopic dermatitis and alopecia areata. The drug candidate is a serpin short peptide, derived from human alpha-1-antitrypsin. The drug candidate is administered through subcutaneous route. It acts by targeting low density lipoprotein receptor related protein 1.
Serpin Pharma overview
Serpin Pharma is a biotech company that provides targeted therapeutics for the treatment of inflammatory diseases. The company’s therapeutic products enhance the body’s natural immune response, reduce inflammation and help to restore the body’s immunity. It offers products in various therapeutic areas to treat acute myocardial infarction (AMI), acute lung injury, acute kidney injury, atopic dermatitis and chronic inflammatory demyelinating polyneuropathy (CIDP), among others. The company collaborates with diversified fields of research companies to develop therapeutics for unmet medical needs. It markets its products through distributors, retailers and third parties. Serpin Pharma is headquartered in Manassas, Virginia, the US.
For a complete picture of SP-16’s drug-specific PTSR and LoA scores, buy the report here.